An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Biocept announces 1-for-30 reverse stock split, trading to begin on split-adjusted basis
Positive
Biocept's common stock will begin trading on a split-adjusted basis
No fractional shares of common stock were issued to any stockholders
Negative
None.
SAN DIEGO--(BUSINESS WIRE)--
Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that as a result of its 1-for-30 reverse stock split that became effective at 4:05 p.m. Eastern Time on May 16, 2023, its common stock will begin trading on a split-adjusted basis with the open of the market today, May 17, 2023. Biocept’s common stock will continue to trade under the existing trading symbol “BIOC.”
As a result of the reverse stock split, each 30 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock. No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.
Stockholders of record will receive information regarding their share ownership following the reverse stock split from the Company’s transfer agent, Continental Stock Transfer & Trust. Continental Stock Transfer & Trust can be reached at (800) 509-5586 or (212) 509-4000 or by email at cstmail@continentalstock.com.
For additional information regarding the reverse stock split, please refer to Biocept’s Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 16, 2023.
About Biocept
Biocept is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. Our experts have spent years working to change the way physicians look at cerebrospinal fluid (CSF) in cancer patients. Biocept has developed a unique, patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, Biocept is a leading commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample.
Investor and Media Contact:
Jody Cain, LHA Investor Relations
Jcain@lhai.com, 310-691-7100
Source: Biocept, Inc.
FAQ
What is the trading symbol for Biocept's common stock?
Biocept's common stock will continue to trade under the existing trading symbol 'BIOC.'
How many pre-split shares of common stock were combined into one issued and outstanding share?
Each 30 pre-split shares of common stock outstanding were automatically combined and converted into one issued and outstanding share of common stock.
Will stockholders receive fractional shares of common stock?
No fractional shares of common stock were issued to any stockholders in connection with the reverse stock split. Holders of record will receive a cash payment in lieu of fractional shares.
How can stockholders contact Biocept's transfer agent for information regarding their share ownership?
Stockholders can contact Continental Stock Transfer & Trust at (800) 509-5586 or (212) 509-4000 or by email at cstmail@continentalstock.com.
Where can I find additional information about the reverse stock split?
Additional information can be found in Biocept's Current Report on Form 8-K, filed with the Securities and Exchange Commission on May 16, 2023.
biocept is a molecular oncology diagnostics company specializing in biomarker analysis of circulating tumor associated dna , both in circulating tumor cells (ctcs) and in plasma (cell free circulating tumor dna). our mission is to improve outcomes for cancer patients by advancing oncology diagnostics. we utilize patented and innovative technologies to deliver clinically relevant oncology diagnostics to physicians by providing advanced prognostic and predictive assessments for guiding the course of treating patients. additionally, we offer services to other laboratory testing providers, academic institutions, research organizations, biopharmaceutical companies, and clinical trial support. our strategic focus is to promote our unique targeted selector™ technology to the oncology community. our target selector technology has demonstrated that it can consistently capture extremely rare cells which may be present in only 1 of every 50-100 billion blood cells. examples of these rare cells ar